Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMICUS THERAPEUTICS, INC.FOLD · Entity 51196 | Chief Financial Officer | January 17, 2023 | January 19, 2023 |
| Amylyx Pharmaceuticals, Inc.AMLX · Entity 259 | Director | June 04, 2026 | June 08, 2026 |
| Century Therapeutics, Inc.IPSC · Entity 5739 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMICUS THERAPEUTICS, INC.
Report date January 17, 2023 · Filed January 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 398,532 |
Ending reported balance
After 2023-01-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-01-17 · Sale · Disposed 5,000 · Balance 405,455 F1: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.34 to $12.70. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2023-01-18 · Sale · Disposed 6,923 · Balance 398,532 F1: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.34 to $12.70. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Amylyx Pharmaceuticals, Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.31 · Expires 2036-06-03 | Direct | 24,372 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 24,372 · Balance 24,372 F1: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Century Therapeutics, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.24 · Expires 2036-06-11 | Direct | 74,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 74,000 · Balance 74,000 F1: The option vests on the earlier of (a) June 11, 2027, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of (a) June 11, 2027, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 21:07 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 74,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001543031-26-000002 · form4-06122026_090652.xml · derivative · entry 1 Quimi Daphne · CIK 0001543031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,000 Underlying: Common Stock · 74,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 11, 2027, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 24,372 | $0.00 Strike: $14.31 | $0.00 |
DisclosureSEC source: 0001193125-26-261640 · ownership.xml · derivative · entry 1 Quimi Daphne · CIK 0001543031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,372 Underlying: Common Stock · 24,372 shares Expires 2036-06-03 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 22:24 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001062993-25-011784 · form4.xml · derivative · entry 1 Quimi Daphne · CIK 0001543031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2035-06-12 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 12, 2026, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:07 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0000950170-25-083717 · ownership.xml · derivative · entry 1 Quimi Daphne · CIK 0001543031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2026 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| September 12, 2024 Filed Sep 16, 2024 20:18 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | PurchaseCommon Stock | 5,000 | $1.53 | $7,657.00 |
DisclosureSEC source: 0001062993-24-016641 · form4.xml · nonDerivative · entry 1 Quimi Daphne · CIK 0001543031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.525 to $1.54. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:50 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001062993-24-012905 · form4.xml · derivative · entry 1 Quimi Daphne · CIK 0001543031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2034-06-20 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 20, 2025, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:42 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0000950170-24-070769 · ownership.xml · derivative · entry 1 Quimi Daphne · CIK 0001543031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 6, 2025 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| May 15, 2024 Filed May 16, 2024 23:37 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | PurchaseCommon Stock | 2,250 | $1.89 | $4,252.28 |
DisclosureSEC source: 0000950170-24-061294 · ownership.xml · nonDerivative · entry 2 Quimi Daphne · CIK 0001543031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| May 14, 2024 Filed May 16, 2024 23:37 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | PurchaseCommon Stock | 2,750 | $1.89 | $5,183.75 |
DisclosureSEC source: 0000950170-24-061294 · ownership.xml · nonDerivative · entry 1 Quimi Daphne · CIK 0001543031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,750 Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 20:19 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001062993-23-014166 · form4.xml · derivative · entry 1 Quimi Daphne · CIK 0001543031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2024-06-27 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 27, 2024, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 23:39 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 16,985 | $0.00 Strike: $26.25 | $0.00 |
DisclosureSEC source: 0000899243-23-015408 · doc4.xml · derivative · entry 1 Quimi Daphne · CIK 0001543031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,985 Underlying: Common Stock · 16,985 shares Expires 2033-06-08 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 8, 2024 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 23:16 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,923 | $13.00 | $89,999.00 |
DisclosureSEC source: 0001209191-23-004080 · doc4.xml · nonDerivative · entry 2 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,532 F1 · kind: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 23:16 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 5,000 | $12.49 | $62,444.50 |
DisclosureSEC source: 0001209191-23-004080 · doc4.xml · nonDerivative · entry 1 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,455 F1 · kind: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.34 to $12.70. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 22:16 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 29,565 | $12.02 | $355,371.30 |
DisclosureSEC source: 0001209191-23-003306 · doc4.xml · nonDerivative · entry 2 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,455 Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 22:16 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 58,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003306 · doc4.xml · nonDerivative · entry 1 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,020 F1 · price: Granted for the achievement of the 2020 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 22:05 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 3,884 | $12.03 | $46,724.52 |
DisclosureSEC source: 0001209191-23-002400 · doc4.xml · nonDerivative · entry 1 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,196 Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 00:13 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 130,480 | $0.00 Strike: $11.93 | $0.00 |
DisclosureSEC source: 0001209191-23-001394 · doc4.xml · derivative · entry 4 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,480 Underlying: Common Stock · 130,480 shares Expires 2033-01-03 F2 · derivative.exercise_date: These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 00:13 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 8,575 | $11.93 | $102,299.75 |
DisclosureSEC source: 0001209191-23-001394 · doc4.xml · nonDerivative · entry 3 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,080 Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 00:13 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 73,508 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001394 · doc4.xml · nonDerivative · entry 2 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,655 F1 · shares: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in four equal annual installments beginning on January 3, 2024 and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document |
| January 02, 2023 Filed Jan 5, 2023 00:13 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 15,165 | $12.21 | $185,164.65 |
DisclosureSEC source: 0001209191-23-001394 · doc4.xml · nonDerivative · entry 1 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,147 Read SEC document |
| October 01, 2022 Filed Oct 3, 2022 20:08 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 39,744 | $0.00 Strike: $9.89 | $0.00 |
DisclosureSEC source: 0001062993-22-020144 · form4.xml · derivative · entry 1 Quimi Daphne · CIK 0001543031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,744 Underlying: Common Stock · 39,744 shares Expires 2032-10-01 F1 · derivative.exercise_date: Century Therapeutics, Inc. (the "Company") issued Ms. Quimi stock options (the "Options") in connection with her appointment as a director. The Options vest in equal monthly installments over 36 months subject to Ms. Quimi's continued service to the Company and are issued pursuant to the Company's 2021 Equity Incentive Plan. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 21:05 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 4,397 | $11.29 | $49,620.58 |
DisclosureSEC source: 0001209191-22-048797 · doc4.xml · nonDerivative · entry 1 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,312 F1 · kind: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.99 to $11.57. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 22:02 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 5,798 | $12.00 | $69,576.00 |
DisclosureSEC source: 0001209191-22-045060 · doc4.xml · nonDerivative · entry 1 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,709 F1 · kind: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 20:01 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 4,396 | $9.00 | $39,564.00 |
DisclosureSEC source: 0001209191-22-038365 · doc4.xml · nonDerivative · entry 1 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,507 F1 · kind: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:05 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0000899243-22-021886 · doc4.xml · derivative · entry 1 Quimi Daphne · CIK 0001543031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 23:42 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 18,843 | $10.53 | $198,416.79 |
DisclosureSEC source: 0001209191-22-003818 · doc4.xml · nonDerivative · entry 2 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,903 Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 23:42 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 36,840 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-003818 · doc4.xml · nonDerivative · entry 1 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,746 F1 · price: Granted for the achievement of the 2019 PRSU TSR goal as determined by the Board of Directors. Read SEC document |
| January 06, 2022 Filed Jan 11, 2022 01:31 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (Right to Buy) · Derivative | 8,400 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001517 · doc4.xml · derivative · entry 1 Quimi Daphne · CIK 0001543031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 Underlying: Common Stock · 8,400 shares Expires 2032-01-06 F1 · derivative.exercise_date: This option shall vest in full on the date of the Corporation's 2022 Annual Stockholders Meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 02:01 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 4,041 | $12.48 | $50,431.68 |
DisclosureSEC source: 0001209191-22-001205 · doc4.xml · nonDerivative · entry 5 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,906 Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:01 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 134,044 | $0.00 Strike: $12.11 | $0.00 |
DisclosureSEC source: 0001209191-22-001205 · doc4.xml · derivative · entry 6 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,044 Underlying: Common Stock · 134,044 shares Expires 2032-01-03 F3 · derivative.exercise_date: These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:01 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 73,136 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-001205 · doc4.xml · nonDerivative · entry 4 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,947 F1 · shares: Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock. F2 · price: The Restricted Stock Units will vest in four equal annual installments beginning on January 3, 2023. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:01 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 1,538 | $12.11 | $18,625.18 |
DisclosureSEC source: 0001209191-22-001205 · doc4.xml · nonDerivative · entry 3 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,811 Read SEC document |
| January 02, 2022 Filed Jan 5, 2022 02:01 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 15,778 | $11.55 | $182,235.90 |
DisclosureSEC source: 0001209191-22-001205 · doc4.xml · nonDerivative · entry 2 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,349 Read SEC document |
| December 31, 2021 Filed Jan 5, 2022 02:01 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 10,502 | $11.55 | $121,298.10 |
DisclosureSEC source: 0001209191-22-001205 · doc4.xml · nonDerivative · entry 1 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,127 Read SEC document |
| April 06, 2021 Filed Apr 9, 2021 00:01 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 19,295 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026161 · doc4.xml · nonDerivative · entry 1 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,629 F1 · security: Granted in the form of Restricted Stock Units for the achievement of the 2019 PRSU Revenue goal. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock. The Restricted Stock Units will vest on December 31, 2021, subject to the reporting person's continued service with the Company. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 22:38 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 16,628 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001209191-21-019155 · doc4.xml · derivative · entry 3 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,628 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the options were fully vested and exercisable as of the transaction date. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 22:38 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 4,664 | $10.48 | $48,878.72 |
DisclosureSEC source: 0001209191-21-019155 · doc4.xml · nonDerivative · entry 2 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,334 F1 · shares: Represents shares exchanged to cover the strike price of the options exercised. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 22:38 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 16,628 | $2.94 | $48,886.32 |
DisclosureSEC source: 0001209191-21-019155 · doc4.xml · nonDerivative · entry 1 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:17 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 4,770 | $21.84 | $104,152.95 |
DisclosureSEC source: 0001209191-21-004472 · doc4.xml · nonDerivative · entry 2 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,370 Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:17 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 9,502 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-004472 · doc4.xml · nonDerivative · entry 1 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,140 F1 · price: Granted for the achievement of the 2018 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 00:43 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 53,355 | $0.00 Strike: $21.78 | $0.00 |
DisclosureSEC source: 0001209191-21-001653 · doc4.xml · derivative · entry 5 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,355 Underlying: Common Stock · 53,355 shares Expires 2031-01-04 F3 · derivative.exercise_date: These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 00:43 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 33,131 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-001653 · doc4.xml · nonDerivative · entry 4 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,638 F1 · shares: Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock. F2 · price: The Restricted Stock Units will vest in four equal annual installments beginning on January 4, 2022. Read SEC document |
| January 03, 2021 Filed Jan 6, 2021 00:43 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 5,053 | $23.09 | $116,673.77 |
DisclosureSEC source: 0001209191-21-001653 · doc4.xml · nonDerivative · entry 3 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,507 Read SEC document |
| January 02, 2021 Filed Jan 6, 2021 00:43 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 15,164 | $23.09 | $350,136.76 |
DisclosureSEC source: 0001209191-21-001653 · doc4.xml · nonDerivative · entry 2 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,560 Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 00:43 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 2,620 | $23.09 | $60,495.80 |
DisclosureSEC source: 0001209191-21-001653 · doc4.xml · nonDerivative · entry 1 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,724 Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 22:45 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001209191-20-065059 · doc4.xml · derivative · entry 3 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,628 Underlying: Common Stock · 5,000 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the options were fully vested and exercisable as of the transaction date. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 22:45 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 5,000 | $24.09 | $120,473.50 |
DisclosureSEC source: 0001209191-20-065059 · doc4.xml · nonDerivative · entry 2 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,344 F1 · kind: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $23.60 to $24.45. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 22:45 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 5,000 | $2.94 | $14,700.00 |
DisclosureSEC source: 0001209191-20-065059 · doc4.xml · nonDerivative · entry 1 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:32 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 6,892 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001209191-20-064062 · doc4.xml · derivative · entry 9 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,892 shares Expires 2024-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the options were fully vested and exercisable as of the transaction date. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:32 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 4,379 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-20-064062 · doc4.xml · derivative · entry 8 Quimi Daphne · CIK 0001543031 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,379 shares Expires 2023-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the options were fully vested and exercisable as of the transaction date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.